IL1B and lung carcinoma: The aim of our study was to investigate whether a defined cytokine panel (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, IFN-α, IFN-γ, TNF-α) can play a prognostic or predictive role in lung cancer patients treated with immune checkpoint inhibitors to assess any potential correlations between their serum levels and clinical safety and the treatment response.